诚意药业: 浙江诚意药业股份有限公司关于回购完成暨回购实施结果的公告

Summary of Key Points Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. has successfully completed its share repurchase plan, utilizing a total of approximately 76.4 million yuan to buy back 9,618,796 shares, which represents 2.94% of its total share capital. The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3]. Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on October 1, 2024, with a planned implementation period from September 30, 2024, to September 29, 2025 [1]. - The expected repurchase amount ranges from 50 million yuan to 100 million yuan [1]. - The repurchase was conducted through centralized bidding, with the actual repurchase price ranging from 7.25 yuan to 8.36 yuan per share, and an average price of 7.94 yuan per share [3]. Group 2: Implementation Status - As of the announcement date, the company has reached the lower limit of the repurchase amount, completing the share repurchase plan [3]. - The total amount paid for the repurchased shares was 76,397,831.64 yuan, excluding transaction fees [3]. - The company used its own funds and a special bank loan for the repurchase, ensuring that the operation would not significantly impact its business, finances, or future development [3]. Group 3: Shareholder Transactions - There were no stock trading activities by the actual controller, major shareholders, directors, supervisors, or senior management from the date of the initial disclosure of the repurchase plan until the announcement date [3]. Group 4: Future Plans for Repurchased Shares - The repurchased shares will be used for employee stock ownership plans, as approved in a board meeting held on August 11, 2025 [4][5].